Arecor Therapeutics announced plans to cease operations within its subsidiary Tetris Pharma during 2025 on Friday, adding ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Shares in Cambridge biopharma company Arecor Therapeutics hit a 52-week low at 54.75p on Friday before recovering to close at ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Arecor Therapeutics PLC (GB:AREC) has released an update. Arecor Therapeutics PLC has appointed David Ellam as the Interim Chief Financial Officer, bringing over two decades of experience in the ...

Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform ...

Arecor Therapeutics has entered into an exclusive licensing agreement for AT351, a ready-to-dilute liquid formulation of a critical care therapy, with a major chemicals marketing company’s ...

Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its developmental portfolio of biologic drugs, which are based on already-marketed drugs ...

Arecor Therapeutics has signed an exclusive licensing agreement for AT351, its ready-to-dilute (RTD) liquid drug product, ...

Licensee gains exclusive rights to further develop and commercialise AT351 -AT351 has potential to be the first ...

(Sharecast News) - Arecor Therapeutics announced plans to cease operations within its subsidiary Tetris Pharma during 2025 on Friday, adding that it had mutually agreed with Xeris BioPharma to ...